MOUNTAIN VIEW, Calif., Aug. 8, 2016 /PRNewswire/ -- CyberHeart Inc. announced today its first development agreement in Asia, with the installation of the CyberHeart System at the National Cancer Center (NCC) in Tokyo. This is the world's first system to non-invasively treat patients with cardiac radiosurgery in Asia.
"We are excited to offer our patients the most advanced, painless and non-invasive treatment for cardiovascular conditions, and thrilled to be the first center in Asia to offer the use of this breakthrough technology," said Jun Itami, MD, PhD, and chair of the Department of Radiation Oncology, National Cancer Center. "The CyberHeart System allows patients to undergo ablation for cardiac arrhythmias and other vascular conditions as an outpatient. The personalized nature of the ablation allows the treatment to be tailored to the patient's individual anatomy."
NCC expects to begin treating patients shortly, and intends to develop various treatment protocols and subsequently publish their research.
"A non-invasive treatment approach to cardiac arrhythmias should significantly benefit patients with and without malignancy, and clearly enhance their quality of life," said Masaaki Shoji, MD, cardiologist at NCC.
"The installation at NCC is the beginning of international activity for CyberHeart, as this therapy is embraced by physicians in the treatment of cardiac conditions," said Patrick Maguire, MD, PhD, President and CEO of CyberHeart. "We are delighted to work with this world-class institution to broaden the scope of therapy and bring it to additional patients."
CyberHeart is a privately held medical device company located at The Fogarty Institute for Innovation in Mountain View, Calif. The company is focused on the development of radiosurgery for cardiovascular conditions. The CyberHeart System uses image-guided tracking of intra-cardiac and other ablation targets, so clinicians can contour and target ablation sites specific to a given patient's anatomy. It is the world's first non-invasive robotic assisted ablation treatment for cardiac conditions. CyberHeart™ and CardioPlan™ are registered trademarks of CyberHeart Inc.
National Cancer Center was established in 1962 by the Japanese government as the first national hospital and research institute specializing in cancer patient management and basic and translational research of cancer. It is one of the two hospitals of the National Cancer Center, Japan, and is supported by the Ministry of Health, Labor and Welfare of the Japanese Government. NCC in Tokyo began treating patients in 1962, and is dedicated to providing the best medical care to its patients, including those with cancer. The center offers state-of-the-art therapy in radiosurgery and a world-class R&D capability.
About The Fogarty Institute of Innovation
The Fogarty Institute for Innovation is a 501(c)(3) non-profit that helps early-stage medical companies transform their ideas into medical products that improve patient care. Carefully selected medical innovators are offered workspace, research and development resources, financial aid, and world-class mentoring by physicians and industry experts to bring their products to market. The Institute was founded in 2007 by internationally renowned cardiovascular surgeon and innovator Dr. Thomas J. Fogarty, M.D., and it is based on the El Camino Hospital campus in Mountain View, Calif. To learn more, visit www.fogartyinstitute.org, and follow the Institute on Facebook and Twitter.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cyberheart-announces-development-agreement-with-national-cancer-center-in-japan-to-treat-cardiac-arrhythmias-300309625.html
SOURCE CyberHeart Inc.